Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label, Multicenter Phase II Study of the C5a Antibody IFX-1 Alone or IFX-1 + Pembrolizumab in Patients With PD-1 or PD-L1 Resistant/Refractory Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC)

NCT04812535 is registered in ClinicalTrials.gov with InflaRx GmbH as lead sponsor.

NCT NCT04812535
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04812535 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label, Multicenter Phase II Study of the C5a Antibody IFX-1 Alone or IFX-1 + Pembrolizumab in Patients With PD-1 or PD-L1 Resistant/Refractory Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC)
Lead sponsor
InflaRx GmbH
Phase
Phase 2
Overall status
Terminated
Start date
March 31, 2021
Completion date
June 4, 2024
Enrollment
30 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

scc - squamous cell carcinoma of skin